Pazopanib Hydrochloridis CAS 635702-64-6 Puritas >99.0% (HPLC) API Factory

Description:

Nomen chemicum: Pazopanib hydrochloride

CAS: 635702-64-6

Aspectus: Alba ad leviter Yellow pulveris

Puritas: >99.0% (HPLC)

Receptor kinasus tyrosinus inhibitor ad curationem carcinoma renum processit vel textus mollis sarcoma provectus

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Manufacturer Supple cum High puritate et stabulo Quality
Nomen chemicum: Pazopanib hydrochloride
CAS: 635702-64-6
Receptor kinasus tyrosinus inhibitor ad tractandum carcinoma renum promota vel sarcoma mollis textus, qui chemotherapy prior accepit.
API High Quality, Commercial Production

Chemical Properties:

Nomen chemicum	Pazopanib Hydrochloride
Synonyma	Pazopanib HCl;GW786034 HCl;Votrient;5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Hydrochloride
CAS Number	635702-64-6
CATTUS Number	RF-API93
Stock Status	In Stock, Productio Ascendite usque ad Centum chiliogrammata
Formulae hypotheticae	C21H23N7O2S.ClH
M. Pondus	473.987
Solubilitas	DMSO
Liquescens punctum	300.0~304.0℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Leviter flavo pulveris albi
Lepidium sativum	Infraed effusio spectri experimenti concordat cum signo
Residere in Ignition	≤0.50%
Omnis immunditia	≤0.30%
Totalis immunditias	≤1.50%
Metalla gravis	≤10ppm
Puritas / Analysis Methodus	≥99.0% (HPLC)
Test Standard	Enterprise Standard
Consuetudinem	API, Tyrosine kinase receptor inhibitor

Sarcina & Repono:

sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.

commoda:

FAQ:

Applicatio:

Hydrochloridum pazopanib (CAS 635702-64-6) est kinasus multi-tyrosinus inhibitor incrementi vascularii endothelialis factoris receptoris (VEGFR)-1, VEGFR-2, VEGFR-3, factor incrementi receptae (PDGFR) -α et - β, factor incrementi fibroblast receptor (FGFR) -1 et -3, receptor cytokinus (Kit), interleukin-2 receptor-inducibilis T-cellula kinasus (Itk), lymphocyte-specialis interdum tyrosinus kinasus (Lck), et glycoprotein receptor tyrosinus kinase (cFms).In vitro, pazopanib inhibuit ligandi autophosphorylationem VEGFR-2, Kit, et PDGFR-BETAE receptorum.In vivo, pazopanib inhibuit VEGF-VEGFR effecerunt phosphorylatio 2 in muris pulmonis, angiogenesis in muris exemplar, et incrementa quorundam tumoris humani xenografts in muribus.Probatum est pro renum carcinoma ab US Food et medicamentum Administration in MMIX et sub nomine Votrient mercatus est a fabrica pharmaci, GlaxoSmithKline.Inhibitor kinasus Votriens est indicatus curationi aegrorum cum: 1) carcinoma renum cell.2) Sarcoma quae prior chemotherapy accepit, mollis textus provectus est.